Skip to main content
Fig. 6 | Pediatric Rheumatology

Fig. 6

From: Safety and effectiveness of intravenous abatacept for polyarticular-course juvenile idiopathic arthritis: An all-case postmarketing surveillance study

Fig. 6

Time course of MMP-3. The MMP-3 levels at baseline and 24 and 52 weeks after administration of abatacept are shown for overall patients (a), nonresponders (b), and responders (c). Responders for abatacept were defined as patients with 2.0 or less in JADAS-27 (CRP) at 52 weeks after abatacept administration with data imputation using the last observation carried forward (LOCF) method. MMP-3, matrix metalloproteinase-3; CRP, C-reactive protein

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096